ESGCT2025: iBET Presents Latest Advances in Gene Therapy Development and Advanced Cell Models
32nd Annual Congress of the European Society of Gene & Cell Therapy
iBET researchers recently presented their latest research in Gene Therapy tools and advanced cell model development at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), held in Seville, Spain from October 7-10.
Highlights from iBET’s participation included an oral presentation and chairing of a scientific session:
- Ana Sofia Coroadinha (Head of the Cell Line Development and Molecular Virology Lab – CLMV) chaired the session “Manufacturing I: Delivery Technologies”
- Isabella Ramela Gal (PhD Student at the Advanced Cell Models Lab) delivered an oral presentation titled “A human 3D liver model to unravel rAAV-driven innate immune responses”. This work focuses on developing a human 3D model mimicking the liver microenvironment to investigate how different liver cell compartments contribute to the innate immune response to recombinant adeno-associated viruses (rAAVs). This project was developed in collaboration with Boehringer Ingelheim (BI).
Moreover, scientists from the CLMV Lab also presented two posters:
- Sofia Fernandes shared insights on “Impact of AAV2 Rep expression in HEK293 cells: towards stable rAAV production”. This work was also developed in collaboration with BI.
- Gabriela Silva presented “Improving AAV transduction efficiency by capsid engineering with nuclear localization peptides”
Founded in 1992, ESGCT promotes basic and clinical research in gene therapy, cell therapy and genetic vaccines. It facilitates education, technology exchange, and serves as a professional advisor to stakeholder communities and regulatory bodies in Europe. This year’s edition was co-organized with the Spanish Society for Gene and Cell Therapy.
The event brought together global experts in the field to collaborate, showcase and discuss the latest advancements in Gene Therapy, Cell Therapy and Genetic Vaccines.
